Class-action lawsuits allege securities fraud against Altimmune Inc. for overstating pemvidutide's potential.

Class-action lawsuits filed against Altimmune Inc. allege securities fraud, claiming the company overstated the potential of its lead product candidate, pemvidutide, and its clinical, commercial, and competitive prospects. Investors who purchased Altimmune shares between December 1, 2023, and April 26, 2024, may be eligible for recovery. Law firms representing investors include Levi & Korsinsky, Bronstein, Gewirtz & Grossman, and Bernstein Liebhard LLP.

May 07, 2024
9 Articles